Geniposide attenuates epilepsy symptoms in a mouse model through the PI3K/Akt/GSK-3β signaling pathway

HONGTAO WEI, GUANGHUI DUAN, JIANXUN HE, QINGLONG MENG, YUXIAN LIU, WANQIANG CHEN and YONGPENG MENG

Department of Neurosurgery, The Second People's Hospital of Gansu Province, Lanzhou, Gansu 730000, P.R. China

Received January 30, 2016; Accepted October 18, 2017

DOI: 10.3892/etm.2017.5512

Abstract. Previous reports on the pharmacological actions of geniposide have indicated that it has anti-asthmatic, anti-inflammatory and analgesic effects in the liver and gall-bladder, and therapeutic effects in neurological, cardiovascular and cerebrovascular diseases. The results of the current study demonstrate that geniposide attenuates epilepsy in a mouse model through the phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt)/glycogen synthase kinase-3β (GSK-3β) signaling pathway. A mouse model of epilepsy was induced by maximal electric shock (50 mA, 50 Hz, 1 sec). Epilepsy mice were intragastrically administered with 0, 5, 10 or 20 mg/kg geniposide. Geniposide significantly reduced the incidence and significantly increased the latency of clonic seizures in epileptic mice compared with non-treated epileptic mice (both P<0.01). Geniposide treatment significantly inhibited cyclooxygenase-2 mRNA expression in epilepsy mice (P<0.01). Furthermore, geniposide significantly suppressed the protein expression of activator protein 1, increased the activation of Akt and increased the protein expression of GSK-3β and PI3K in epilepsy mice (all P<0.01). These results suggest that geniposide attenuates epilepsy in mice through the PI3K/Akt/GSK-3β signaling pathway.

Introduction

The primary goal when treating epilepsy is to prevent seizures with minimal side effects to increase patients' quality of life (1,2). In China, there are ~9 million people with epilepsy, 6 million of which are diagnosed with active epilepsy. Each year, 0.4 million new cases are reported (3). Mortality risk for epilepsy patients is 2-3 times higher than that of the normal population. Although multiple drug therapies exist for epilepsy, anti-epilepsy drugs are not effective for one-third of patients (4). These drugs only try to control the symptoms of epilepsy, and do not affect the occurrence or pathological processes of the disease (5).

Previous studies have indicated that autoimmune disorders, such as systemic lupus erythematosus and vasculitis, are important causes of epilepsy (6). Invasion of activated microglial cells, inflammatory media and lymphocytes in infant brains can trigger autoimmune disorders, which can lead to catastrophic epilepsy in children (7). In addition, patients with autoimmune diseases of the central nervous system or N-methyl-D-aspartate receptor encephalitis are at a high risk of epilepsy (8). Inflammation is a key factor in the occurrence and recurrence of epilepsy and has been associated with its pathological severity (9).

Epilepsy is a disease of the nervous system. Repeated attacks can result in brain neuron injuries or patient fatality (10). The phosphatidylinositol-3-kinase (PI3K)/protein kinase B (Akt) signal transduction pathway is a key intra-cellular survival pathway (11). Whether cell apoptosis occurs or not largely depends on activation of the PI3K/Akt signal transduction pathway and a cascade of downstream signals (12).

*Gardenia jasminoides* Ellis is principally grown in Zhejiang, Fujian, Jiangxi, Hunan and Guangdong in China. Geniposide is derived from *G. jasminoides* Ellis and previous studies have suggested that it can be used to reduce fever, acute icteric hepatitis, cystitis and upper gastrointestinal hemorrhage (13-15). The present study aimed to investigate whether geniposide treatment could reduce epilepsy symptoms in a mouse model through the PI3K/Akt/glycogen synthase kinase-3β (GSK-3β) signaling pathway.

Materials and methods

*Animals.* All experimental protocols were performed in accordance with the guidelines of the Institutional Animal Care and Use Committee of The Second People's Hospital of Gansu Province (Lanzhou, China). Ethical approval was granted by the Ethics Committee of the Second People's Hospital of Gansu Province. A total of 38 C57Bl/6 mice aged 11-12 weeks (20-23 g, male) obtained from Medical Experimental Center of Lanzhou University (Lanzhou, China) were used in the present study and housed in an animal laboratory (temperature, 22±1°C; humidity, 55±5%) on a 12 h light/dark cycle.

*Correspondence to:* Dr Hongtao Wei, Department of Neurosurgery, The Second People's Hospital of Gansu Province, 1 Hezhengxi Road, Lanzhou, Gansu 730000, P.R. China

E-mail: wazhi58975444@126.com

*Key words:* geniposide, epilepsy, inflammation, protein kinase B, glycogen synthase kinase-3β
Mouse model of epilepsy and grouping. A mouse model of epilepsy was induced by maximal electric shock (50 mA, 50 Hz, 1 sec) through ear clip electrodes using a stimulator apparatus, as previously described (16). Mice were randomly assigned into the following groups: Sham (10 ml/kg saline, n=6), epilepsy model (10 ml/kg saline, n=8), 5 Gen group (5 mg/kg geniposide, n=8), 10 Gen group (10 mg/kg geniposide, n=8) and 20 Gen group (20 mg/kg geniposide, n=8). Saline and geniposide were administered intra-gastrically. Geniposide was purchased from Sigma-Aldrich (Merck KGaA, Darmstadt, Germany) and its chemical structure is shown in Fig. 1.

Stereotaxic surgery and kindling procedure. Mice were anesthetized with intravenous injection of 60 mg/kg ketamine and 10 mg/kg xylazine (Sigma-Aldrich; Merck KGaA) and then stereotaxically implanted with bipolar stimulating and monopolar recording stainless-steel Teflon-coated electrodes (A-M Systems, Sequim, WA, USA; -2.5 mm from bregma, 4.8 mm lateral and 7.4 mm ventral to dura). An additional electrode was attached to a skull screw and fixed to the left cortical surface with dental acrylic. At four weeks after treatment with geniposide, the after discharge (AD) threshold was recorded in the amygdala using a 2-sec stimulus (100 Hz, 1 msec/pulse). Stimulation was initially delivered at 50 µA with 5-min intervals. Then stimulus intensity was increased by 50 µA, which was delivered until at least 5 sec of AD threshold was recorded. AD threshold was measured once a day until three consecutive stage 5 seizures were observed. The seizure stages were defined as follows: Stage 1, facial clonus; stage 2, head nodding; stage 3, forelimb clonus; stage 4, rearing and bilateral forelimb clonus; stage 5, rearing, loss of balance and falling (17). In the sham group, mice were anesthetized as above and no surgical procedures were performed. Following induction of the AD model, all mice were immediately weighed and were subsequently weighed at weeks 1, 2, 3 and 4.

Clonic seizures or generalized seizures. Mice that appeared less active and exhibited fremitus, mutation, scratching, face twitching or disequilibrium were considered to experience clonic seizures. Mice were scored as follows; 0 seizures, stage 1; 1 seizure, stage 2; 2 seizures, stage 3; 3 seizures, stage 4; >3 seizures, stage 5. The incidence (%) of clonic seizures was calculated using the following formula: (number of clonic seizures/total number of mice) x100. The number of mice exhibiting each seizure stage (1-5 stages) was expressed as S. The incidence (%) of generalized seizures was calculated as follows: (S/total number x5) x100.

Reverse transcription-quantitative polymerase chain reaction (RT-qPCR). Following 4 weeks of treatment with geniposide, mice were sacrificed by decapitation under anesthetization (intravenous injection of 35 mg/kg pentobarbital sodium (Sigma-Aldrich; Merck KGaA). Total RNA was extracted from blood using an Easy Total RNA Extraction kit (Tiangen Biotech Co., Ltd., Beijing, China). Total RNA (1 µg) was converted to cDNA using the ReverTra ACE-α-RNAeasy kit (Toyobo Co., Ltd., Osaka, Japan). The Bio-Rad CFX96 Real-Time system (Bio-Rad Laboratories, Inc., Hercules, CA, USA) was performed to analyze the mRNA expression of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2). The primers used were as follows: iNOS forward, 5’-GCTCGTTTTGCGACGACGA-3’ and reverse, 5’-AAGGCAGGGGCAATGCAAA-3’; COX-2 forward, 5’-GGGCTCAGCCAGGCAGCAAT-3’ and reverse, 5’-GACTCTGTTTGGGGTGGCCT-3’; β-actin forward, 5’-CTGCTCCGTGATGCTCTGCT-3’ and reverse, 5’-ATGTACGCGACGGATTCCC-3’. A custom PCR master mix (Tiangen Biotech Co., Ltd., Beijing, China) was used. The reaction conditions were as follows: 95°C for 45 sec, followed by 40 cycles of 95°C for 30 sec, 55°C for 40 sec and 72°C for 30 sec.

Western blot analysis. Hippocampus tissue samples were homogenized using radioimmunoprecipitation assay buffer (Beyotime Institute of Biotechnology) and protease/phosphatase inhibitor cocktail (EMD Millipore, Billerica, MA, USA). The cell lysate was centrifuged at 12,000 x g for 10 min at 4°C and the supernatant was collected. Protein concentrations were determined using a bicinchoninic acid protein assay kit (Beyotime Institute of Biotechnology). Proteins (20 µg) were separated by 8-12% SDS-PAGE and transferred to polyvinylidene difluoride membranes. The membranes were blocked with 5% bovine serum albumin (Nanjing SunShine Biotechnology Co., Ltd., Nanjing, China) for 1 h at room temperature and probed with anti-AP-1 (1:3,000), anti-P13K (sc-7174; 1:2,000), anti-Akt (sc-8312; 1:2,000) and anti-phosphorylated (p)-Akt (sc-7985-R; 1:5,000; all Genetimes Technology, Inc., Shanghai, China), anti-GSK-3β (sc-7879; 1:2,000; Santa Cruz Biotechnology, Inc., Dallas, TX, USA) and anti-β-actin (sc-7210; 1:5,000; Genetimes Technology, Inc.) overnight at 4°C. The membranes were then washed with TBS with Tween-20 and incubated with horseradish peroxidase-conjugated secondary antibody (sc-2004; 1:5,000; Santa Cruz Biotechnology, Inc.) at 37°C for 1 h. The results were visualized using an enhanced chemiluminescence substrate reagent kit (EMD Millipore). Protein expression was measured using the ChemiDoc™ XRS luminescent image analyzer and Image Lab version 2.0.1 software (both Bio-Rad Laboratories, Inc.).

Statistical analysis. All values are presented as the mean ± standard error of the mean. Statistical analysis was performed using SPSS 17.0 software (SPSS, Inc., Chicago, IL, USA) and the two-tailed Student’s t-test or one-way analysis
of variance. P<0.05 was considered to indicate a statistically significant difference.

Results

Effect of epilepsy and geniposide treatment on mouse weight. At one week after geniposide treatment, the epilepsy model mice weighed less than the Sham group (P<0.01; Fig. 2). The weights of the epilepsy model mice increased from week 2 to 4, but remained lower than the Sham group throughout the experimental period (P<0.01; Fig. 2).

Effect of geniposide on clonic seizures in mouse epilepsy. In the current study, the effects of geniposide treatment on the incidence and latency of clonic seizures in mice epilepsy were evaluated. The incidence of clonic seizures was significantly higher in the epilepsy model control group compared with the sham group (P<0.01; Fig. 3A). The latency of clonic seizures was significantly reduced in the epilepsy model control group compared with the sham group (P<0.01; Fig. 3B). However, geniposide treatment (10 or 20 mg/kg) significantly reduced the incidence and significantly increased the latency of clonic seizures compared with the epileptic model control group (both P<0.01; Fig. 3A and B).

Effect of geniposide on generalized seizures in mouse epilepsy. The epileptic model control group showed a significant increase in the incidence of generalized seizures compared with the sham group (P<0.01; Fig. 4A). A significant reduction was observed in the incidence of generalized seizures
after geniposide treatment. However, there was a significant increase in AD duration in the epilepsy model control group compared with the sham group (P<0.01; Fig. 4B) and geniposide treatment (10 or 20 mg/kg) significantly attenuated AD duration compared with the epilepsy model control group (P<0.01; Fig. 4B).

**Effect of geniposide on iNOS mRNA expression in mouse epilepsy.** The level of iNOS mRNA expression in epileptic mice was analyzed using RT-qPCR. As shown in Fig. 5, there was no significant difference in iNOS mRNA expression between the sham group and the epileptic model control, or between the epileptic model control and the geniposide-treated epileptic groups.

**Effect of geniposide on COX-2 mRNA expression in mouse epilepsy.** The level of COX-2 mRNA expression in epileptic mice was analyzed using RT-qPCR. As shown in Fig. 6, COX-2 mRNA expression was significantly higher in the epilepsy model control group compared with the sham group (P<0.01). Furthermore, treatment with geniposide (10 or 20 mg/kg) significantly inhibited the epilepsy-induced COX-2 mRNA expression compared with the epileptic model control (P<0.01).

**Effect of geniposide on AP-1 protein expression in mouse epilepsy.** The level of AP-1 protein expression was evaluated by western blot analysis. As shown in Fig. 7, AP-1 protein expression was significantly higher in the epilepsy model control group compared with the sham group (P<0.01). Furthermore, treatment with geniposide (10 or 20 mg/kg) significantly suppressed AP-1 protein expression compared with the epileptic model control (P<0.01).

**Effect of geniposide on GSK-3β protein expression in mouse epilepsy.** The level of GSK-3β protein expression was evaluated by western blot analysis. As shown in Fig. 8, GSK-3β protein expression was significantly lower in the epilepsy model control group compared with the sham group (P<0.01). Furthermore, geniposide treatment (10 or 20 mg/kg) significantly promoted GSK-3β protein expression compared with the epileptic model control (P<0.01).

**Effect of geniposide on PI3K protein expression in mouse epilepsy.** The level of PI3K protein expression was evaluated by western blot analysis. As shown in Fig. 9, PI3K protein expression was significantly lower in the epilepsy model control group compared with the sham group (P<0.01). Furthermore, geniposide treatment (10 or 20 mg/kg) significantly promoted PI3K protein expression compared with the epileptic model control (P<0.01).

**Effect of geniposide on Akt protein expression in mouse epilepsy.** In order to investigate the anti-apoptosis effects of geniposide on Akt protein expression in mice epilepsy, Akt and p-Akt protein expression was evaluated by western blot analysis (Fig. 10). The p-Akt/Akt rate was significantly reduced in the epilepsy model control group compared with the sham group (P<0.01). Furthermore, treatment with geniposide (10 or 20 mg/kg) significantly increased the p-Akt/Akt rate compared with the epileptic model control (P<0.01).

**Discussion**

As a paroxysmal minimal brain dysfunction, epilepsy is characterized by acute spasms. The morbidity rate of epilepsy is 24-53/100,000 in developed countries and 77-114/100,000 in developing countries (18). The morbidity rate in children is 151/10,000 (19). To the best of our knowledge, the present study is the first to demonstrate a protective effect of geniposide in mouse epilepsy, through a reduction in clonic.
beta reported that geniposide increases Akt, protein kinase B; p-Akt, phosphorylated Akt.

10 Gen, 10 mg/kg geniposide group; 20 Gen, 20 mg/kg geniposide group; Model, epilepsy model control group; 5 Gen, 5 mg/kg geniposide group.

p-Akt/Akt rate.

Figure 10. Effect of geniposide treatment on Akt protein expression in mouse epilepsy. (A) Western blot analysis and (B) quantification of Akt protein expression, expressed as p-Akt/Akt rate. *P<0.01 vs. Sham; **P<0.01 vs. Model. Sham, sham group; Model, epilepsy model control group; 5 Gen, 5 mg/kg geniposide group; 10 Gen, 10 mg/kg geniposide group; 20 Gen, 20 mg/kg geniposide group; Akt, protein kinase B; p-Akt, phosphorylated Akt.

Nitric oxide (NO) has a dual function of neuroprotection and neurovirulence in the central nervous system (20). Previous results indicated that NO and NO synthase were significantly elevated in the brains of epilepsy patients, which may be related to cell damages after an attack of epilepsy (21). Previous research also confirmed that cell apoptosis after epilepsy was related to overexpression of NO, which demonstrated that iNOS was more closely related with apoptosis (22). Another study demonstrated that a selective iNOS inhibitor could significantly reduce the expression of caspase-3 (23). The results of the current study suggested that geniposide treatment did not significantly affect iNOS mRNA expression in mouse epilepsy. Zhang et al proposed that geniposide inhibits LPS-induced iNOS expression in N9 microglial cells (24).

COX-2 participates in pathological processes such as inflammation and tumor invasion (25). It has been found that multiple stimuli, including cytokines, hormones, ischemia, hypoxemia, epilepsy and phorbol ester can increase the expression of COX-2 (26). In the majority of cells, COX-2 expression can increase rapidly after an attack of epilepsy or cerebral ischemia and can be inhibited by corticosteroids (27). Therefore, it is dynamically regulated. The results of the current study indicated that geniposide reduces COX-2 mRNA expression in mouse epilepsy. Shi et al reported that geniposide suppresses lipopolysaccharide (LPS)-induced iNOS and COX-2 signaling pathways in macrophages (28).

Previous results have indicated that activated AP-1 is a key transcription factor for inflammatory responses and causes severe inflammatory reactions, disturbs neural pathways, influences nerve conduction and impairs tissues (29). A previous study confirmed that the majority of inflammatory mediators are regulated by transcription factors (29). AP-1 may regulate the expression of inflammatory factors and therefore affect the severity of inflammation and the efficacy of therapeutic strategies (29). AP-1 is a homodimer or heterodimer of c-fos and c-jun. Under basal conditions, the concentration and activity of AP-1 are relatively low (30). When cells are stimulated, AP-1 expression increases (30). The results of the current study indicated that geniposide reduces AP-1 protein expression in mouse epilepsy. Shi et al demonstrated that geniposide suppresses the LPS-induced inflammatory cytokine, prostaglandin E2, and NO through inhibition of AP-1 signaling pathways in macrophages (28).

Akt has been demonstrated to be the direct downstream substrate of PI3K (10). As an inhibitor of PI3K can block the activation of Akt, the activation status of PI3K/Akt pathways can be predicted by observing the expression of p-Akt (10). Previous results have suggested that apoptosis plays an important role in cerebral neuron death after epilepsy (31). As a key component of survival signal, Akt is necessary to cellular survival triggered by growth factors, extra-cellular matrix and other stimulus (31). Activated Akt is a cellular survival factor that can help cells escape from programmed cell death by inactivating multiple effector molecules of apoptosis (32). In the present study, it was demonstrated that geniposide induces PI3K/Akt pathways in mice epilepsy. Guo et al reported that geniposide increases insulin secretion in pancreatic β-cells through involvement of PI3K (33). Park et al suggested that geniposide may suppress
transforming growth factor-β1/epithelial-mesenchymal transition and activate Akt signaling pathways in AML12 hepatocytes (34).

Composed of 23 sub-units of GSK-3α and GSK-3β, GSK-3 is a serine/threonine kinase (35). It is a key component of multiple signal transduction pathways and is closely associated with cell differentiation, proliferation and apoptosis, and diseases such as diabetes, cancer and neurodegenerative disease (36). GSK-3β has been indicated to be extensively distributed in rat cerebral tissues, with high levels of expression in the hippocampus (36). A previous study on epilepsy reported that GSK-3β could hyperphosphorylate microtubule-associated protein tau. P-tau proteins are key components of neurofibrillary tangles in epilepsy (35). Previous research has also reported that excessive p-tau protein is related to cognitive impairment in Alzheimer's disease (37). In the present study, it was demonstrated that geniposide attenuates GSK-3β protein expression in mice epilepsy. Collectively, Zhang et al reported that insulin-deficient APP/PS1 transgenic and GSK-3β protein expression in mouse model of Alzheimer's disease (38).

In conclusion, the present study demonstrated that geniposide attenuates clonic seizures and generalized seizures in mice epilepsy. Furthermore, the current results indicate that geniposide reduces COX-2 and AP-1 expression, and that the underlying mechanism of geniposide involves the PI3K/Akt/GSK-3β signaling pathway to adjust neurocyte apoptosis. These findings may be beneficial for developing effective treatment strategies for epilepsy.

Acknowledgements

The present study was supported by the Health Industry Scientific Research Projects in Gansu Province (grant no. GSWST2012-07).

References


